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Summary
Dendritic cells (DCs) are key instigators of adaptive
immune responses. Using an alphaviral expression
cloning technology, we have identified the chemokine
CCL19 as a potent inducer of T cell proliferation in a
DC-T cell coculture system. Subsequent studies showed
that CCL19 enhanced T cell proliferation by inducing
maturation of DCs, resulting in upregulation of costi-
mulatory molecules and the production of proinflam-
matory cytokines. Moreover, CCL19 programmed DCs
for the induction of T helper type (Th) 1 rather than
Th2 responses. Importantly, only activated DCs that
migrated from the periphery to draining lymph nodes,
but not resting steady-state DCs residing within
lymph nodes, expressed high levels of CCR7 in vivo
and responded to CCL19 with the production of proin-
flammatory cytokines. Migrating DCs isolated from
mice genetically deficient in CCL19 and CCL21 (plt/
plt) presented an only partially mature phenotype,
highlighting the importance of these chemokines for
full DC maturation in vivo. Our findings indicate that
CCL19 and CCL21 are potent natural adjuvants for
terminal activation of DCs and suggest that chemo-
kines not only orchestrate DC migration but also reg-
ulate their immunogenic potential for the induction of
T cell responses.
Introduction
Dendritic cells (DCs) are key initiators of innate and
adaptive immunity (for review, see Banchereau et al.,
2000; Lanzavecchia and Sallusto, 2001; Mellman and
Steinman, 2001). They are potent antigen-processing
and -presenting cells with the unique ability to stimu-*Correspondence: martin.bachmann@cytos.com
4 These authors contributed equally to this work.late primary immune responses in addition to boosting
secondary immune responses. Immature DC precur-
sors exit the bone marrow and circulate via the blood-
stream to reach their target tissues, taking up residence
at sites of potential pathogen entry in a physiological
stage that is specialized for antigen capture (Steinman,
1991). After uptake of antigen by phagocytosis, via
macropinocytosis or via receptor-mediated endocyto-
sis (Albert et al., 1998; Sallusto et al., 1995), the antigen
is processed and peptides thereof are presented on the
cell surface associated with the MHC class I or II mole-
cules. After receiving maturation-inducing signals, either
directly from pathogens or via inflammatory stimuli,
DCs change the expression pattern of chemokine re-
ceptors, allowing them to leave the peripheral tissue
and to migrate to draining lymphoid organs (Rescigno
et al., 1999). Upregulation of CCR7 during maturation
renders DCs sensitive to two chemoattractants, ELC/
CCL19 and SLC/CCL21, which direct their migration to
T cell regions of lymphoid organs (Cyster, 1999; Sal-
lusto and Lanzavecchia, 2000). Within these regions,
DCs can induce both activation and proliferation of
specific CTLs and Th cells via presentation of immuno-
genic peptides in association with MHC class I and II
molecules, respectively. In addition to protection against
pathogens, DCs also appear to be central to the regula-
tion, maturation, and maintenance of cellular immune
responses against cancer (Gunzer et al., 2001; Timmer-
man and Levy, 1999). Recently, it has emerged that DCs
not only induce T cell responses but are equally impor-
tant for the maintenance of peripheral T cell tolerance
because resting DCs induce T cell tolerance rather than
immunity (Bonifaz et al., 2002; Probst et al., 2003).
Thus, regulation of DC activation is critical for the es-
tablishment of protective T cell responses as well as
for the maintenance of T cell tolerance (for review, see
(Bachmann and Kopf, 2002)).
Pathogen-mediated DC activation is usually trans-
duced via the Toll-like receptor (TLR) family (Akira,
2001; Beutler, 2002; Medzhitov and Janeway, 2000).
TLR recognize invariable patterns associated with
pathogens like peptidoglycans (TLR2) (Takeuchi et al.,
1999), double-stranded RNA (TLR3) (Alexopoulou et
al., 2001), LPS (TLR4) (Hoshino et al., 1999; Poltorak
et al., 1998), flagellin (TLR5) (Hayashi et al., 2001), and
bacterial RNA (TLR 7/8) (Diebold et al., 2004; Heil et al.,
2004) or DNA (TLR9) (Hemmi et al., 2000; Schnare et
al., 2000). Activation of dendritic cells is also induced
by proinflammatory cytokines and in particular by
members of the TNF superfamily, including TNF-α,
CD40L, and Trance/RANKL (Bachmann et al., 1999;
Cella et al., 1996; Koch et al., 1996; Wong et al., 1999).
Recently, chemokine receptors have also been shown
to be directly involved in induction of DC maturation.
Specifically, activation through CCR5 by T. gondii-
derived cyclophilin led to production of high levels of
IL-12 in DCs (Aliberti et al., 2000; Aliberti et al., 2003).
The importance of DC maturation for the generation of
protective T cell responses is also highlighted by the
fact that several viruses interfere with activation of DCs.
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494Poxviruses inhibit DC maturation by lowering the ex- b
lpression of CD86, leading to reduced T cell costim-
ulation (Engelmayer et al., 1999). Along a similar line, m
iherpes simplex virus inhibits maturation of DCs (Salio
et al., 1999), and measles virus induces an aberrant p
imaturation program resulting in inhibition rather than
activation of T cells (Schneider-Schaulies et al., 2003).
To identify novel proteins capable of regulating T cell C
responses through the activation of DCs, we performed T
an alphavirus based expression cloning campaign. We t
used Sindbis virus as a carrier of a normalized cDNA c
library from activated splenocytes and generated a pro- v
tein library by infection of baby hamster kidney (BHK) f
cells (Koller et al., 2001). Sindbis virus belongs to the a
alphavirus genus and contains a single-stranded RNA s
genome with positive polarity. Using a bipartite system, 2
where one RNA molecule encodes the structural pro- T
teins and the other encodes the protein of interest plus p
the viral replicase, it is possible to generate replication w
competent viruses encoding genes or even libraries of t
interest (Koller et al., 2001). d
We report here the identification of mouse CCL19 T
and CCL21 as potent maturation factors for DCs and o
indirect regulators of Th cell differentiation. Our findings f
indicate that induction of DC maturation is an important A
property of CCL19/CCL21 and suggest that chemo- o
kines may not only organize the migration of DCs but S
also directly regulate their ability to prime T cell re- t
sponses. i
c
wResults
d
CIdentification of CCL19 by Expression Cloning
Because DCs are crucial for the induction of immune
Presponses, we set out to identify novel DC maturation
ifactors using an alphaviral screening technology. In or-
Tder to generate a Sindbis virus-based cDNA library,
CRNA was extracted from spleens of LCMV-infected
tBALB/c mice, transcribed into cDNA and normalized as
pdescribed in the Experimental Procedures. The cDNA
Flibrary was transformed into a viral library by in vitro
utranscription and electroporation together with a viral
phelper construct (Koller et al., 2001).
wFollowing the strategy shown in Figure 1A, BHK cells
Awere infected at a multiplicity of infection (MOI) of 0.1
Oand single infected cells were sorted on subconfluent
pBHKs in 96-well plates. This led to the generation of a
uprotein library within 3 days, where each well corres-
aponded to the expression of one cDNA-derived protein.
uThe protein-containing supernatants were harvested,
aand remaining virus was inactivated by UV light.
aSpleen-derived DCs were pulsed with OVA peptide and
btreated with the supernatants overnight. The next day,
tOVA-specific CD4+ T cells were added, and prolifera-
Ction was assessed 2.5 days later by 3H-thymidine incor-
poration.
The average counts per plate were calculated and C
Mevery supernatant that induced a count/min value two
standard deviations above the average was retested by T
rthe same assay. From those wells that scored positive
a second time, the virus-encoded cDNA was recovered t
pby RT PCR, and the cDNA sequence was determined
(Figure 1B). In total 10,000 genes derived from the li- crary were tested for their ability to enhance T cell pro-
iferation in the assay. Besides known inducers of DC
aturation, like hsp70, the chemokine CCL19 was
dentified twice independently in this screening cam-
aign. One of the plates in which CCL19 was identified
s shown in Figure 1B.
CL19 Induces Maturation of Dendritic Cells
o confirm that CCL19 induces T cell proliferation in
he DC-T cell coculture system, the CCL19 cDNA was
loned into the alphaviral vector, and the recombinant
irus was generated (SR5-CCL19). BHK cells were in-
ected, and the supernatant was retested in the prolifer-
tion assay. In these experiments, the proliferation-
timulating activity of CCL19 was confirmed (Figure
A). In order to assess whether CCL19 directly induces
cell proliferation, naïve T cells were incubated in the
resence or absence of CCL19. No T cell proliferation
as induced by CCL19 (data not shown), suggesting
hat the observed induction of T cell proliferation is me-
iated solely through enhancement of DC maturation.
o test this further, spleen-derived DCs were treated
vernight with the supernatants and analyzed for sur-
ace expression of CD40 and CD86 by flow cytometry.
significantly higher proportion of mature DCs were
bserved in cultures treated with supernatants from
R5-CCL19-infected BHK cells compared to DC cul-
ures treated with supernatants from control virus-
nfected BHK cells (Figures 2B and 2C). As a positive
ontrol, we included Sindbis virus-expressing TNF-α,
hich enhanced T cell proliferation (Figure 2A) and in-
uced DC maturation in a manner comparable to
CL19 (Figures 2B and 2C).
urified CCL19 Enhances Proliferation of T Cells
n the DC-T Cell Coculture System
o test whether the effects found where specific for
CL19 and not due to the use of a viral expression sys-
em, an N-terminal FLAG-tagged CCL19 protein was
roduced in HEK 293 cells and purified over an anti-
LAG column (Figure 3A). This purified protein was
sed for all further experiments. First, the proliferation
romoting quality in the DC-T cell coculture system
as retested. Bone marrow-derived DCs were taken as
PCs, and proliferation was tested at three different
VA peptide concentrations. DCs were pulsed with the
eptide for 1 hr and then treated with the different stim-
li for 4 hr. OVA-specific T cells were subsequently
dded and proliferation was measured 3 days later (Fig-
re 3B). In a similar experiment, T cell proliferation was
ssessed by CSFE staining. DCs were treated as above
nd incubated for 4 days with CSFE-labeled T cells. In
oth experiments, CCL19 enhanced T cell proliferation
o the same extent as treatment with LPS plus anti-
D40 antibodies or TNF-α (Figure 3C).
CL19 Induces Upregulation of Costimulatory
olecules and the Production of Cytokines in DCs
he maturation of DCs is associated with the loss of
eceptors involved in antigen uptake and the upregula-
ion of costimulatory molecules that are important for
roductive interaction with T cells. Through the con-
omitant production of cytokines, DCs can further pro-
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495Figure 1. Outline of the Screening Strategy with CCL19 Highlighted as One of the Results of the Screening Campaign
(A) BHK cells were infected at a MOI of 0.1 with Sindbis virus encoding genes from a normalized cDNA library derived from activated mouse
spleens. Infected BHK cells (stained with anti-Sindbis-specific antibody) were sorted one cell/well on BHK cells seeded in 96-well plates.
After 3 days propagation, the supernatant of the infected wells were harvested, treated with UV-light to inactivate virus, and transferred onto
OVA peptide-pulsed spleen-derived DCs. Following overnight treatment, purified CD4+ DO11.10 T cells were added to the wells, and prolifera-
tion of T cells was measured by incorporation of 3H-thymidine.
(B) A 96-well plate is shown where one well showed substantially increased proliferation of OVA-specific CD4+ T cells (encircled point). RNA
from the positive well was extracted, transcribed by RT-PCR into cDNA, and sequenced. The virus-encoded gene was CCL19. Dotted line
indicates the average counts/min of the plate.mote the induction of an immunological response fol-
lowing pathogen exposure. In order to analyze the
maturation program triggered in DCs by CCL19, we ex-
amined the surface expression of CD40, CD80, CD86,
MHC II, and, additionally, the levels of the proinflamma-
tory cytokines interleukin-1 beta (IL-1β), interleukin-12
(IL-12), and tumor necrosis factor alpha (TNF-α).
In the first instance, DCs were treated overnight and
the surface expression of CD40, CD80, CD86, and MHC
II was assessed by flow cytometry (Figures 4A and 4B
and Figure S1 in the Supplemental Data available with
this article on line). To exclude that the observed effect
was due to LPS contamination, the samples were
treated with proteinase K and subsequent heat dena-
turation. CCL19 was found to induce upregulation ofCD86 (Figure 4A) and CD40 (Figure 4B) in an LPS-inde-
pendent fashion, shown by a loss of function following
proteinase K treatment. Similar upregulation of CD86
and CD40 was found for CCL19 as for TNF-α and LPS
treatment (Figures 4A and 4B). To further ensure that
the DC maturation effect was mediated by CCL19, we
tested its activity on DCs genetically deficient in the
CCL19 receptor, CCR7. The CCL19-induced DC matu-
ration was indeed mediated through binding to CCR7
because production of IL-12 (Figure 4C) and upregula-
tion of CD86, CD80, and CD40 surface expression was
not evident after stimulation of CCR7−/− DC by CCL19
(Figure 4D). Of note, the activity of CCL19 was Pertus-
sis toxin sensitive and also independent of MyD88
(data not shown). We next performed titration experi-
Immunity
496Figure 2. Cloned CCL19 Expressed by Sindbis Virus Enhances T Cell Proliferation and Induces Maturation of DCs
The cDNA encoding CCL19 was cloned into a Sindbis virus expression vector, and recombinant viruses expressing CCL19 were generated
(SR5-CCL19).
(A) UV-inactivated supernatants of control, SR5-TNF-α, or SR5-CCL19 virus-infected BHK cells were tested in the DC-T cell coculture system
as described in Figure 1. Error bars represent the standard deviation of triplicates.
(B and C) Spleen derived DCs were treated overnight with UV light-inactivated control Sindbis virus (SR5), Sindbis virus-expressing TNF-α
(SR5-TNF-α), or CCL19 (SR5-CCL19). Following overnight incubation, DCs were stained with anti-CD40 and anti-CD86 antibodies and ana-
lyzed by flow cytometry. The frequency of mature DCs (oval gate) was determined. In (C), the frequency (±SD) of mature DCs is shown for
triplicate cultures. One representative experiment of two similar experiments is shown in (A)–(C).ments and found that CCL19 induced DC maturation at p
sconcentrations of 0.1 g/ml and higher (Figures 4E and
4F), roughly corresponding to chemokine concentra- c
ttions used to induce cellular migration (Figure 4G) (see
also Kwan and Killeen, 2004; Moutaftsi et al., 2004). m
oTwo commercially available CCL19 batches pro-
duced in a prokaryotic expression system were also l
ttested and found to be less active. This limited activity
correlated with a roughly 100-fold reduced ability of the (
scommercial CCL19 to induce migration of DCs (data
not shown). Thus, in our experimental system, commer- S
Tcial bacterially expressed CCL19 appears to have an
overall limited potency. p
dTo test whether CCL19 induced secretion of relevant
inflammatory cytokines, supernatants of the stimulated
DCs were analyzed for the presence of IL-1β and IL-12 C
T(p40) by ELISA. CCL19 induced strong production of
both cytokines (Figure 5A). Induction of IL-12 pro- a
pduction was similar to LPS-treated DCs, whereas IL-1βroduction was even higher than that seen after LPS
timulation. In comparison to TNF-α, CCL19 induced
learly higher levels of both IL-12 and IL-1β. In addi-
ional experiments, we compared induction of inflam-
atory cytokines by CCL19 with combined stimulation
f DCs with LPS and anti-CD40 antibodies. This stimu-
us has recently been shown to be sufficient for induc-
ion of autoimmunity by using peptide-pulsed DCs
Eriksson et al., 2003). Cytokine production was as-
essed by intracellular cytokine staining (Figure 5B).
urprisingly, CCL19 induced similar levels of IL-1β,
NF-α, and IL-12 as compared to stimulation with LPS
lus anti-CD40 antibodies, confirming that CCL19 is in-
eed a strong maturation trigger for DCs (Figure 5B).
CL21 Also Induces Maturation of DCs
o test whether the second ligand of CCR7, CCL21,
lso induces maturation of DCs, we expressed and
urified a FLAG-tagged version of CCL21 as described
CCL19 Is a Potent Activator of DCs
497Figure 3. Purified Recombinant CCL19 En-
hances Peptide-Specific Proliferation in a
DC-T Cell Coculture Assay
(A) CCL19 was subcloned into an eukaryotic
expression vector to produce an N-terminal
FLAG-tagged CCL19 protein. 293-EBNA
cells were transfected and FLAG-CCL19 was
purified from supernatants over an anti-
FLAG column. Purified recombinant FLAG-
tagged CCL19 was analyzed on a Coomas-
sie-stained protein gel (left) and by Western
blot stained with an anti-FLAG antibody
(right).
(B) OVA-pulsed (0, 10−8 M, 10−7 M, or 10−6 M)
bone marrow-derived DCs were treated with
PBS, LPS and anti-CD40 antibodies (0.1 µg/
ml/5 µg/ml), TNF-α (50 ng/ml), or CCL19
(0.33 µg/ml) for 4 hr. OVA-specific transgenic
CD4+ T cells were added and the prolifera-
tion was assessed by 3H-Thymidine incorpo-
ration. Error bars represent standard devia-
tion of triplicate wells.
(C) OVA-pulsed (10−8 M) bone marrow-
derived DCs were activated as described in
(B), then OVA-specific CSFE-labelled CD4+ T
cells were added, and after 4 days incuba-
tion, analyzed for CSFE staining. Data in (B)
and (C) are from independent experiments,
and comparable data were found in a sim-
ilar experiment.for CCL19. Bone marrow-derived dendritic cells were
then stimulated with titrated amounts of FLAG-CCL21
and analyzed for the expression of CD86 and CD40.
As observed for CCL19, CCL21 was able to strongly
stimulate DC maturation at concentrations above 0.1
g/ml (Figure S2).
CCL19 Primes DCs for the Induction
of Th1 Responses
We sought to determine whether CCL19 stimulation of
DCs would preferentially facilitate the induction of
either Th1 or Th2 responses. Accordingly, we employed
the use of a DC-transgenic T cell coculture system
where T helper cell differentiation is controlled by pep-
tide concentration (Marsland et al., 2004; Ruedl et al.,
2000a). In this coculture system, high concentrations of
peptide result in Th1 differentiation and IFN-γ pro-
duction, while low concentrations of peptide result in
Th2 differentiation and IL-4 production. Dendritic cells
were incubated for 4 hr in the presence or absence of
CCL19, washed twice, and used to stimulate CD4+
TCR-transgenic T cells from SMARTA mice (Oxenius et
al., 1998) specific for peptide GP13 derived from LCMV.
To ascertain whether CCL19 was capable of directly ac-
tivating T cells, naïve T cells were also incubated for 4
hr in the presence or absence of CCL19 before use in
the coculture. A peptide concentration of 100 nM wasused in these cultures because this induces differentia-
tion of both Th1 and Th2 cells, allowing any additional
polarizing effects mediated by CCL19 to be identified.
After 3 days of culture, production of IL-4 and IFN-γ by
the transgenic CD4+ T cells was assessed by intracel-
lular cytokine staining. As expected, untreated DCs
pulsed with 100 nM GP13 induced both Th1 and Th2
cells, as shown by the presence of both IL-4- and
IFN-γ-producing cells (Figure 6, left panel). In marked
contrast, DCs activated with CCL19 preferentially medi-
ated Th1 development, increasing the proportion of
IFN-γ-producing cells and decreasing the proportion of
IL-4-producing cells (Figure 6, middle panel). Preincu-
bating T cells with CCL19 did not influence T cell differ-
entiation, indicating that the effect of CCL19 was lim-
ited to the activation of DCs (Figure 6, right panel).
Taken together, these data show that CCL19 selectively
mediates induction of Th1 responses.
TLR-Activated Migratory DCs Are Licensed
for CCL19-Mediated Activation
In addition to the previously described chemoattractive
properties of CCL19, we have shown that it can directly
activate DCs and lead to the production of proinflam-
matory cytokines and upregulation of costimulatory
molecules. However, the constitutive production of
CCL19 within lymphoid tissues would not be expected
Immunity
498Figure 4. Purified Eukaryotic CCL19 Induces Maturation of BM-DCs
(A and B) BM-DCs were treated overnight with PBS, TNF-α (50 ng/ml), LPS (1µg/ml), or FLAG-CCL19 (0.33µg/ml), without proteinase K
treatment (black bars) or after proteinase K treatment (white bars) and stained for the expression of CD86 and CD40. The error bars represent
the standard deviation of quadruplicates.
(C) CCR7−/− or wild-type DC were activated with CCL19, and the proportion of IL-12-producing cells was determined by flow cytometry.
Numbers represent percentage of CD11c+ IL-12+ cells.
(D) Surface expression of CD86, CD80, and CD40 was determined by flow cytometry for CCL19-stimulated control and CCR7-deficient DCs.
(E and F) BM-DCs were treated overnight with titrated amounts of FLAG-CCL19 and expression of (E) CD86 and (F) CD40 was assessed by
flow cytometry. Error bars represent the standard error of the mean for quadruplicate cultures. Horizontal lines indicate expression levels of
DCs cultured in the absence of FLAG-CCL19. GMFI indicates geometric mean fluorescence intensity.
(G) Migration of DCs in response to the indicated concentrations of FLAG-CCL19 was examined as described in the Materials and Methods.
In the presented assay, nonspecific migration was 3.2 × 103 ± 0.8 × 103 DCs. Error bars represent the standard deviation for triplicate cultures.
Data in (A), (B), (E), and (F) represent combined values from two experiments. Data in (C), (D), and (G) are from independent experiments that
were repeated with comparable results.
CCL19 Is a Potent Activator of DCs
499Figure 5. CCL19 Induces Secretion of Inflammatory Cytokines
(A) Bone marrow-derived DCs were treated with PBS, TNF-α (50 ng/ml), LPS (1µg/ml), or FLAG-CCL19 (0.33µg/ml). 18 hr after addition of
stimuli, the supernatant of these cells were harvested and analyzed with a sandwich-ELISA for the presence of IL-1β and IL-12 (p40). The
error bars represent the standard deviation of triplicates.
(B) After stimulation with PBS, LPS/anti-CD40 antibodies (0.1 µg/ml/5 µg/ml), or FLAG-CCL19 (0.33 µg/ml) for 8 hr, bone marrow-derived DCs
were analyzed for cytokine expression by intracellular staining for IL-1β, TNF-α, and IL-12 (p40). Data are from two independent experiments
and are representative of two (A) or four (B) similar experiments. The error bars represent the standard deviation of triplicates.draining lymph node were semimature/steady-stateOVA protein (FITC-OVA) and LPS via the intranasal
Figure 6. CCL19 Primes DCs for the Induction of Th1 Cytokines
C57BL/6 primary DCs or SMARTA-2 TCR transgenic CD4+ T cells were stimulated with 1 µg/ml CCL19 or medium alone for 4 hr. After washing
twice with medium, naïve DCs together with naïve SMARTA-2 TCR transgenic CD4+ T cells; CCL19-activated DCs together with naïve
SMARTA-2 TCR transgenic CD4+ T cells; or naïve DCs together with CCL19-activated SMARTA-2 TCR transgenic CD4+ T cells, were cultured
in the presence of 100 nM GP13 peptide for 3 days. Following a 4 hr restimulation with PMA and ionomycin, IFN-γ and IL-4 producing TCR-
transgenic T cells were identified by flow cytometry. Numbers represent percentage of CD4+ T cells positive for the indicated cytokine. Data
are from one representative experiment of two similar experiments.to result in the activation of steady-state DCs because
autoimmunity would otherwise result. To examine this
directly, we compared CCR7 expression on semi-
mature/steady-state DCs in the lymph node to that of
DCs that had been activated in the periphery by a TLR
ligand and had migrated to the lymph node to present
exogenous antigen. We administered FITC-conjugatedroute, and 24 hr later, we removed the draining lymph
node and determined which cell populations contained
FITC-OVA. The only cell population positive for FITC-
OVA were CD11chigh MHC IIhigh DCs (Figure 7A), consis-
tent with active transport of the antigen rather than
passive drainage where additional cell populations
would be expected to take-up OVA. Also present in the
Immunity
500Figure 7. Pathogen-Derived Signals Are Required to License DCs for CCL19-Mediated Activation
FITC-conjugated OVA protein and LPS were instilled via the intranasal route into wild-type (A–C) and plt/plt mice (D–E). After 24 hr, the
draining mediastinal lymph node was removed and DCs isolated.
CCL19 Is a Potent Activator of DCs
501DCs that expressed CD11chigh/int and MHC IIint but were
negative for FITC-OVA (Figure 7A). We assessed the
level of CCR7 surface expression on these two DC pop-
ulations and found that the LPS-activated, OVA-pre-
senting CD11chigh MHC IIhigh DCs expressed higher
levels of CCR7 than the semimature/steady-state DCs
(Figure 7A). To determine whether CCR7high TLR ligand-
activated OVA-presenting DCs exhibited a comparable
response to CCL19 as the CCR7low DCs, we next sorted
the respective DC populations by FACS then activated
them for 6 hr with either CCL19 or LPS, and we then
assessed the production of IL-12, IL-10, or the surface
expression of CD40. The TLR ligand-activated OVA-
presenting DCs produced moderate levels of IL-12
without further stimulation ex vivo, reflective of their ac-
tivated in vivo phenotype and possibly an increased
sensitivity to activation during the isolation and sorting
procedure (Figure 7B). Comparatively, the proportion of
CCR7low DCs that produced IL-12 without further stim-
ulation ex vivo was 6-fold lower (Figure 7B). Upon
CCL19 or LPS activation, the TLR ligand-activated
OVA-presenting DCs produced high levels of IL-12 and
upregulated CD40 expression, while the CCR7low DCs
exhibited no response to CCL19 and were slightly re-
active to LPS stimulation (Figure 7B). Overall, these
data indicate that steady-state DCs express lower
levels of CCR7 than DCs activated in the periphery by
antigen- and pathogen-derived signals and are less re-
sponsive to CCL19-mediated activation. Thus, CCL19
preferentially results in the activation of those DCs that
have previously encountered pathogen-associated
signals.
Licensed Dendritic Cells Require CCL19
and CCL21 for Full Maturation In Vivo
We next investigated the role of CCL19 in activating
DCs within an in vivo setting. Mice homozygous for the
paucity of lymph node T cell (plt) mutation do not ex-
press CCL19 or CCL21 protein in secondary lymphoid
organs, although some expression of CCL21 is detecta-
ble in lymphatic endothelium. One consequence of this
mutation is the reduced, but not abolished, migration
of DCs to lymph nodes (Gunn et al., 1999). Using the
same protocol described above, we exposed wild-type
(Figure 7C) and plt/plt (Figure 7D) mice to FITC-OVA in
the presence of the TLR ligand LPS, via the intranasal
route, and then analyzed the migrating DCs in the
draining lymph node 24 hr later. The number of migrat-
ing DCs was reduced in the plt/plt mice as compared to
wild-type mice, however a clear population of CD11chi
FITC+ cells was evident (Figures 7C and 7D), consistent al., 2003). This induces a potent activation program in
(A) DCs were stained with antibodies specific for CD11c, MHC II, and additionally, CCL19-Ig-Cy5. The uptake of OVA protein was determined
by FITC florescence. Solid lines indicate CD11chi MHC IIhi cells; dashed lines indicate CD11chi/int and MHC IIint cells.
(B) DCs expressing the indicated markers were sorted by FACS, then activated in the presence of either CCL19 or LPS for 6 hr. The proportion
of cells producing IL-12 (p40) and IL-10 was determined by intracellular staining, and expression of CD40 determined by surface staining and
flow cytometry. Numbers represent percentage of cells positive for IL-12, or geometric mean of CD40 expression, respectively. Data are from
pooled lymph node cells from 5 mice.
(C and D) FITC-conjugated OVA protein and LPS were instilled via the intranasal route into wild-type mice (C) and plt/plt mice (D), and uptake
of OVA by DCs was monitored 24 hr later by assessing the presence of FITC in the indicated gate (dashed lines) as compared to semimature
DCs (solid lines). In (E), FITC+ cells from the gates indicated in (C) and (D) were assessed for their surface expression of MHC II, CD80, CD86,
and CD40. Numbers represent geometric mean of the respective cell populations.
Data in (A) and (B) and (C)–(E) are from two independent experiments and are representative of two similar experiments.with previous reports (Gunn et al., 1999). Immediately
ex vivo, we examined the surface expression of the ac-
tivation markers MHC II, CD80, CD86, and CD40 on the
migrating DCs by flow cytometry (Figure 7E). Irrespec-
tive of the plt mutation, the migrating DCs exhibited
comparable surface levels of MHC II, however striking
differences in the surface expression of CD80 and CD86,
and a minor difference in CD40, were evident (Figure
7E). This partially activated phenotype of the migrating
DCs in the plt/plt mice highlights the dual role of
CCL19/21 in both the migration and the activation of
TLR-licensed DCs.
Discussion
Regulation of dendritic cell maturation is essential for
the balance between maximal protective T cell re-
sponses and minimal immunopathology. Here, we show
that CCL19, a chemokine attracting DCs from the pe-
riphery to T cell regions of lymphoid organs, is a strong
maturation signal for DCs and the subsequent induc-
tion of a Th1 response.
A key function of chemokines and their receptors is
the orchestration of leukocyte migration (Cyster, 1999;
Sallusto and Lanzavecchia, 2000). Chemokines regu-
late segregation of T areas from B areas in lymphoid
organs and the traffic of lymphocytes between the two
areas. Chemokines are also instrumental for induction
of local inflammation. Leukocytes traverse the endo-
thelium of blood vessels and migrate into inflamed tis-
sues in a three-step process: recognition of endothe-
lium by selectins, activation by chemokines, followed
by firm attachment by integrins (Campbell et al., 2003).
Naïve resting T cells, and a subset of memory T cells,
express the chemokine receptor CCR7, which binds
CCL19 and CCL21 (Ravkov et al., 2003; Sallusto et al.,
1999; Unsoeld et al., 2002). These two chemokines are
constitutively produced in lymphoid organs and attract
T cells to the T regions of these organs. Intriguingly,
DCs, upon activation, also express CCR7 and become
responsive to CCL19/CCL21, which attracts them to
the T regions for optimal T cell priming (Sallusto and
Lanzavecchia, 2000). It is thought that this mechanism
is responsible for the migration of Langerhans cells
from the skin to lymphoid organs upon activation. How-
ever, chemokine receptors may not only be responsible
for cellular migration but also for activation of dendritic
cells. Indeed, it has recently been shown that the C-C
chemokine receptor CCR5 is triggered by cyclophilin
derived from T. gondii (Aliberti et al., 2000; Aliberti et
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ticular IL-12. This CCR5-mediated activation of DCs re- s
sults in induction of a protective Th1 response and w
clearance of the pathogen. However, if over exagger- g
ated, this response may also result in immunopathol- C
ogy (Aliberti et al., 2000). (
The present study extends this concept by showing s
that maturation of DCs, and the production of proin- l
flammatory cytokines, is an important component of w
chemokine biology in general. Specifically, CCL19 was
identified by a global screen for proteins that activate L
DCs as a strong inducer of dendritic cell maturation. In s
fact, CCL19 was more potent than TNF-α or anti-CD40 a
antibodies at inducing the release of proinflammatory u
cytokines such as IL-1. Interestingly, CCL19 alone was l
able to induce high levels of proinflammatory cytokines l
in DCs. However, we cannot exclude at present time C
that trace amounts of LPS in our CCL19 preparations t
or the in vitro conditions per se (such as contact with s
tissue culture plastic) may have primed the DCs for re- k
sponding to the chemokine. From a physiological point c
of view, it seems likely that CCL19 alone may not be a
able to induce the full maturation program in DCs. c
Otherwise it remains difficult to explain why all DCs are t
not mature given they reside in a CCL19 rich lymphoid r
organ. Indeed, resting, immature/steady-state DCs in s
lymph nodes (Ruedl et al., 2000b; Salomon et al., 1998;
Ohl et al., 2004) expressed low levels of CCR7 and did E
not respond with rapid production of inflammatory
Mcytokines upon stimulation with CCL19. Only activated
BDCs that had immigrated from the periphery upon stim-
Nulation with LPS expressed high levels of CCR7 and
T
produced IL-12 upon stimulation with CCL19. Hence, b
DCs apparently need to first be licensed by a microbial r
stimulus before they respond to CCL19 by producing a
ocytokines and upregulating expression of costimula-
otory molecules.
fInterestingly, DCs isolated from plt/plt mice, which do
a
not express CCL19 or CCL21 protein in secondary lym- u
phoid organs, displayed a partially activated phenotype
as compared to wild-type controls. These data suggest C
that whilst the antigen/ TLR-ligand stimulation in the R
periphery was sufficient to induce migration and upreg- L
uulation of MHC II, CCL19/CCL21 was required for full
yactivation. However, we cannot rule out the possibility
tthat other maturation cues might be absent in these
tmice. Junt et al. have previously shown that the im- R
mune response mounted against LCMV is only slightly t
reduced in plt/plt mice (Junt et al., 2002). It is important p
to note that LCMV efficiently replicates in lymphoid or- r
hgans, and in addition, has multiple ways to activate the
binnate immune system. In such a case, taking away just
Aone component of the normal DC-activation process,
a
i.e. CCL19/CCL21, may not be sufficient to significantly c
impair antiviral immune responses. Of note, functions h
other than chemotactic activity have been attributed to d
CCL19 and CCL21 including inducing endocytosis (Ya- (
Tnagawa and Onoe, 2003), dendritic extension (Yana-
pgawa and Onoe, 2002) and inhibition of apoptosis
w(Sanchez-Sanchez et al., 2004). Our data now extend
s
these findings and reveal an important, physiologically R
relevant, role for CCL19 and CCL21 in programming the R
nature of ensuing T cell immune responses. Taken to- p
tgether, these findings may have important implicationsor rational vaccine design and therapy. Lee et al. have
hown that CD4+ T cell responses are enhanced in vivo
hen mice are given plasmid DNA encoding CCR7 li-
ands (Lee et al., 2003), and intratumoral injection of
CL19 has been shown to increase tumor clearance
Hillinger et al., 2003). The underlying mechanism for
uch CCL19-mediated enhanced immune responses is
ikely to be 2-fold, increasing DC and T cell recruitment
hile also directly activating the DCs.
In summary, our data suggest the following model:
angerhans cells and other DCs in peripheral tissues
cavenge antigens and, upon encountering pathogens
nd receiving a stimulus, such as via toll-like receptors,
ndergo an initial activation step. This leads to upregu-
ation of CCR7, and consequent recruitment of DCs to
ymphoid organs. During the process of migration,
CL19/CCL21 induces full maturation of DCs rendering
hem capable of effectively triggering potent T cell re-
ponses once they reach lymphoid organs. Chemo-
ines, such as CCL19/CCL21, therefore not only or-
hestrate immunity through guiding the leukocytes
long the complex pathways of the lymph and blood
irculation but also through regulation of DC matura-
ion. Thus, CCL19/CCL21 ensures both that antigens
each lymphoid organs and that these antigens are pre-
ented in a maximally immunogenic context.
xperimental Procedures
ice
ALB/c and C57BL/6 mice were purchased from Harlan (Horst, The
etherlands) and used between the ages of 8–14 weeks. DO11.10
CR-transgenic mice (Murphy et al., 1990) were obtained from the
reeding colony at the Institut fu¨r Labortierkunde (University of Zu-
ich, Zurich, Switzerland). SMARTA-2 transgenic mice (Oxenius et
l., 1998) were bred at the Cytos breeding colony. Plt/plt mice were
btained from Dr T Junt, University of Zu¨rich. CCR7−/− cells were
btained with the permission of Dr M Lipp (Max-Delbruck Center
or Molecular Medicine). All experiments were performed with the
pproval of the Zurich animal ethics committee. Animals were kept
nder SPF conditions.
onstruction of Normalized cDNA Libraries
NA was isolated from splenocytes of C57BL/6 mice infected with
CMV 8 days earlier. Tester cDNA was produced from poly(A)+ RNA
sing the template switch protocol (Zhu et al., 2001). Photobiotin-
lated poly(A)+ RNA from naïve splenocytes was used as driver for
he normalization. Therefore 10 g RNA was mixed with 30 g pho-
obiotin acetate and irradiated for 20 min using a 300 W Phillips
eflector Floodlamp. Free photobiotin was removed. For hybridiza-
ion, 2 g tester cDNA was mixed with 2 g biotinylated driver
oly(A)+ RNA and 0.2 g oligo-dT (20mer), ethanol precipitated, and
esuspended in formaldehyde hybridization buffer (80% formalde-
yde, 25 mM Hepes [pH 7.5], 250 mM NaCl, and 5 mM EDTA). Hy-
ridization was carried out in an Eppendorf Mastercycler personal.
fter an initial denaturation step, nucleic acid hybridization was
llowed to proceed for 16 hr at 42°C. Unhybridized single-stranded
DNA was purified by streptavidin-mediated removal of RNA/DNA
ybrids and excess driver RNA. Double-stranded cDNA was pro-
uced by PCR, digested with the restriction endonuclease Sfi1
Roche), and cloned into the alphaviral expression vector pDelSfi.
he library plasmid, linearized with NotI or PacI, and the helper
lasmid pDHEB (Bredenbeek et al., 1993), linearized with EcoRI,
ere subjected to SP6 RNA polymerase-mediated in vitro tran-
cription using the mMessage mMachineTM kit (Ambion). Library
NA was coelectroporated with an equimolar amount of helper
NA into 107 baby hamster kidney (BHK) cells. Eighteen hours
osttransfection, cell supernatants were harvested and the viral ti-
ers determined.
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BHK cells were infected with the normalized viral library at a multi-
plicity of infection of 0.1. Two hours later, cells were washed and
further incubated in the presence of a neutralizing anti-Sindbis anti-
body to avoid superinfection. Eight hours postinfection, cells were
detached and stained for the expression of Sindbis virus proteins
and single-cell sorted into a 96-well plate containing BHK cells.
Plates were then incubated for 3 days at 37°C until full cytopathic
effect had developed. A master plate with 50 µl supernatant con-
taining replication competent viruses was made and stored at
−80°C. The remaining supernatants were UV irradiated in order to
inactivate viruses and then used for the DC-T cell proliferation as-
say. The procedure is schematically shown in Figure 1A.
Preparation of Dendritic Cells and T Cells
Immature mouse dendritic cells (DC) were isolated from spleens
and mesenteric lymph nodes of naïve BALB/c mice as described
(Ruedl and Bachmann, 1999). Purified DCs were pulsed with 4 nM
of OVA-peptide (Ovalbumin [OVA] 323–339; ISQAVHAAHAEINEAGR).
OVA-peptide-specific CD4+ T cells were isolated from spleens of
naïve DO11.10 mice using MACS beads according to the instruc-
tions of the supplier (Miltenyi Biotec). Bone marrow-derived den-
dritic cells (BM-DCs) were prepared from bone marrow of naïve
BALB/c mice as described elsewhere (Lutz et al., 1999).
For DC maturation, 50,000 cells in a final volume of 100 l were
pulsed for 4 hr or 18 hr with TNF-α (50 ng/ml; R&D systems) or LPS
(0.1 µg/ml; Sigma-Aldrich; E. coli, 026:B6) with or without anti-CD40
(clone3/23, 5 µg/ml; BD PharMingen) or FLAG-CCL19 (0.33 µg/ml
or 0.99 µg/ml). Alternatively, these samples were treated with 10
µg/ml proteinase K (Sigma-Alrich) for 45 min at 37°C in DPBS (con-
taining Ca2+ and Mg2+) and subsequently boiled at 95°C for 10 min.
The following antibodies were used for staining: FITC-conjugated
anti-CD86, FITC-conjugated anti-CD80, PE-conjugated anti-CD11c,
allophycocyanin-conjugated anti-TNF-α, biotin-conjugated anti-IL-
1β, biotin-conjugated anti-IL-12-p40 (all BD Pharmingen), and
ALEXA633-conjugated Streptavidin (IBA). Dead cells were always
stained with PI and gated out. Intracellular cytokine stainings were
performed according to standard protocols.
For detection of IL-1β and IL-12 produced by BM-DCs, 1 × 105
cells in 100 l media were cultured for 18 hr with the indicated
stimuli. Then the supernatants were analyzed by sandwich ELISA
for IL-1β (R&D Systems) or IL-12 p40 (BD PharMingen). As stan-
dards, recombinant IL-1β and IL-12 (both R&D systems) were used.
To test for T cell polarization, naïve SMARTA-2 mice (Oxenius et
al., 1998) were sacrificed and spleens removed. CD4+ T cells were
isolated by MACS bead separation (Miltenyi, Germany) and were
found to be 90%–95% CD4+ CD62Lhigh by subsequent FACS analy-
sis. Dendritic cells were isolated from naïve wild-type C57BL/6
spleens as previously described (Ruedl and Bachmann, 1999). Iso-
lated T cells (5 × 104 cells/well) and DCs (1 × 104 cells/well) were
cultured in the presence of 100 nM GP13 peptide in 96-well plates
(Corning Incorporated, USA). On day 3 of culture, cells were acti-
vated in the presence of PMA and ionomycin for 4 hr and IFN-γ and
IL-4 production determined by flow cytometry.
Functional Expression Screening of DC Maturation Factors
Maturation of dendritic cells was determined via their capacity to
induce T cell proliferation in the presence of specific antigen.
Briefly, 30,000 naïve OVA-peptide pulsed dendritic cells/well were
seeded in 96-well round-bottom plates. Fifty microliters of UV-irra-
diated viral supernatant containing one protein of the normalized
activated mouse spleen library was added, and the plates were
incubated at 37°C. As controls, supernatants containing virally ex-
pressed TNF-α or supernatants from SR5-infected BHK cells were
used. After 18–20 hr, 50,000 naïve OVA-specific CD4+ cells were
added to each well, and the plates were further incubated for 2.5
days. 3H-thymidine (1mCi/well) was added for the final 14 hr of
culture. Cells were harvested using a multiple-well harvester and
3H-thymidine incorporation was determined in a scintillation
counter. Viral supernatants leading to maturation of dendritic cells
resulting in high 3H-thymidine incorporation into CD4+ cells were
reanalyzed in a second proliferation assay for confirmation.RT-PCR Rescue of Positive Supernatants
RT-PCR was performed on supernatants from wells that showed
increased proliferation rates. Viral RNA was isolated from superna-
tant using the QIAmp Viral RNA Kit (Qiagen). RNA was transcribed
into cDNA using SUPERSCRIPTTM II RNase H-reverse transcrip-
tase (Invitrogen Life Technologies). Complementary RNA was re-
moved by RNase H treatment. The inserts were amplified by PCR
using Expand High Fidelity PCR System (Roche), separated on an
agarose gel, purified, and sequenced.
In order to generate an expression vector for the recombinant
production, CCL19 was amplified by PCR using gene-specific
primers bearing a BamHI-site at N-terminus (5#-atcgcgGATCCCG
GTGCTAATGATGCGGAAGA-3#) and a NheI-site at the C-terminus
(5#-ctatactagctagctcaAGACACAGGGCTCCTTCTGG-3#). This PCR
product was then cloned into pCEP-N-FLAG leading to construct
pCEP-N-FLAG-CCL19. This construct was used for the eukaryotic
production of N-termianlly FLAG-tagged CCL19.
Expression and Purification of the Recombinant Proteins
293-EBNA cells were seeded at a density of 4 × 106 cells/90 mm
plate in DMEM (GIBCO BRL) containing 10% FCS (GIBCO BRL) 1
day prior to transfection. The cells were then transfected with
pCEP-N-FLAG-CCL19 using lipofectamine 2000 (Invitrogen) ac-
cording to the manufacturer’s recommendations. One day after
transfection cells were passaged under puromycin selection. The
resistant population was then further expanded. Serum-free super-
natants were collected and recombinant N-terminal, FLAG tagged
CCL19 was affinity purified using ANTI-FLAG M2-Agarose-sepha-
rose (SIGMA) according to the manufactures instructions. After
extensive dialysis against PBS, the protein was stored in PBS at
4°C. The protein concentration was determined by Bradford assay
(Biorad).
CFSE In Vitro Proliferation Assay
CFSE was purchased from Molecular Probes (Eugene, OR). BM-
DCs were activated as described above for 4 hr. Then DO11.10
transgenic CD4+ T cells were added, obtained by positive MACS
MicroBeads isolation (Miltenyi Biotec) with a purity of at least 90%.
The T cells were labelled with 0.5 µM CSFE by incubation at 37°C
for 10 min. After labelling, the cells were subsequently washed with
PBS at 4°C. After 4 days of incubation, cells were harvested,
stained with PE labelled anti-CD4 mab (0.1 µg/ml; BD PharMingen),
and the CD4+ T cells were analyzed for CSFE staining by FACS
analysis.
DC Chemotaxis Assay
The chemotactic activity of CCL19 was assessed using the
ChemoTx system according to the manufacturer’s instructions
(NeuroProbe, Inc). In brief, aliquots of 20,000 DCs in 25 l media
were placed on a 3 m pore-size filter above wells containing 30
l of CCL19 at the indicated concentrations. The cells were incu-
bated at 37°C for 4 hr and the total number of cells that had mi-
grated through the filter determined by cell counts. Nonspecific
migration was determined by counting wells containing no chemo-
kine. Each assay was performed in triplicate, and values represent
the mean ± SD of total migrating cells.
Activation and Isolation of OVA-Presenting
and Steady-State DCs
Mice were exposed to 100 g FITC-conjugated OVA (Molecular
Probes, Eugene, OR) and 5 g LPS (Sigma-Aldrich; E. coli, 026:B6)
in a total volume of 50 l PBS by intranasal inoculation. After 24 hr,
draining lymph nodes were removed, digested with collagenase
and DCs isolated. Semimature/steady-state DCs were defined as
cells expressing CD11chi/int MHC IIint FITC– and mature/TLR-acti-
vated DCs were defined as cells expressing CD11chi MHC IIhi
FITC+. The distinct cell populations were sorted by FACS and 1 ×
105 total sorted cells were incubated in either medium or medium
supplemented with CCL19 (1 g/ml) or LPS (1 g/ml) for 6 hr (for
cytokine analysis) or 16 hr (for CD40 expression) in round-bottom
96-well plates. Production of IL-12 and IL-10 was determined by
Immunity
504intracellular cytokine staining, and surface expression of CD40 was (
cdetermined by flow cytometry, as described.
E
W
Supplemental Data i
Supplemental Data include two additional figures and can be found i
with this article online at http://www.immunity.com/cgi/content/full/
E22/4/493/DC1/.
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